Summary of key clinical trial outcomes across development phases of ibalizumab.
| Phase | Patient population | Key findings | Primary outcome |
|---|---|---|---|
| Phase I | Treatment-experienced human immunodeficiency virus-1 (HIV-1)-infected adults; multiple dose-escalation cohorts (0.3–25 mg/kg IV) | No severe adverse events at any dose level. Antiviral activity minimal at 0.3 and 1.0 mg/kg; dose-related viral load reductions at higher doses: 0.56 log10 (3 mg/kg), 1.33 log10 (10 mg/kg), 1.11 log10 (25 mg/kg). PK consistent with IgG4 monoclonal antibody. | Safety established; pharmacokinetics characterised; dose-related antiviral activity confirmed; progression to Phase II justified |
| Phase IIb (TMB-202; NCT00784147) | Treatment-experienced adults with HIV-1 (n = 82); optimised background regimen (OBR) provided | 48-week randomised dose-response study. Ibalizumab + OBR superior to OBR alone. Viral suppression deepened with increasing dose. Long-term extension (TMB-311): 11/12 achieved VL < 200 copies/mL; all 12 achieved VL < 50 copies/mL; mean CD4 gain of 99 cells/μL from baseline. | Optimal dosing identified; durable viral suppression and CD4 recovery confirmed over extended follow-up |
| Phase III (TMB-301; NCT02707861) | Heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 (n = 40; ≥ 3 drug-class resistance); failing current regimen | Loading dose 2,000 mg IV then 800 mg IV every 2 weeks plus optimised background therapy (OBT). At week 24: 83% achieved ≥ 0.5 log10 VL reduction; 43% achieved VL < 200 copies/mL; mean CD4 increase of 48 cells/μL. Modelling: 0.95 additional years with CD4 > 200 cells/μL (28% improvement over OBT alone). | Pivotal efficacy confirmed; FDA approval granted March 2018; European Medicines Agency (EMA) approval 2019 |
| Expanded access (TMB-311; NCT01056393) | Heavily treatment-experienced adults with MDR HIV-1 on continuing ibalizumab-based therapy | 48-week safety and efficacy follow-up. TEAEs predominantly mild-to-moderate: diarrhoea (24%), headache (22%), nausea, cough, rash, fatigue (6% each). No new safety signals identified. Real-world use corroborated favourable tolerability. | Long-term safety and tolerability confirmed; real-world effectiveness supports pivotal trial results |
| Observational (NCT05388474) | MDR HIV-1 patients with and without ibalizumab in real-world clinical settings | Ongoing prospective and retrospective cohort study. Common real-world adverse effects: pruritus/rash, diarrhoea, abdominal discomfort; none led to discontinuation. | Real-world evidence accumulating; outcome comparisons between ibalizumab-treated and untreated MDR cohorts anticipated |